My Favourite 5%+ Yields: GlaxoSmithKline plc, Centrica PLC & Vodafone Group plc

Looking for a great dividend yield? Look no further than GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) & Vodafone Group plc (LON:VOD)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Cash

Although there has been a lot of talk recently regarding interest rate rises, it seems clear that rates are unlikely to hit the ‘historic norm’ of 4%-5% for many years to come. Indeed, the Bank of England has even stated that 2%-3% could be the ‘new normal’. With that in mind, high-yielding shares could continue to offer a realistic alternative to savers and income-seeking investors alike. Here are three companies that yield at least 5% and trade at an attractive price.

GlaxoSmithKline

GlaxoSmithKline (LSE: GSK) continues to see its share price underperform due to weak sentiment rather than doubts surrounding its long term potential. The pharmaceutical giant is subject to various bribery allegations that have caused shares in the company to fall by 8% in the last three months alone.

However, with a highly diversified drugs pipeline that has huge potential, GlaxoSmithKline could see its share price rise over the longer term. In the meantime, a dividend yield of 5.5% is highly attractive, while a price to earnings (P/E) ratio of 13.1 highlights that the present time could be an opportunity to buy in at a low price.

Centrica

As with GlaxoSmithKline, Centrica (LSE: CNA) is suffering from weak sentiment. It is set to change its management team in the near future (with BP’s Iain Conn replacing Sam Laidlaw on 1 January 2015) and is subject to continuing uncertainty regarding domestic energy prices post the 2015 general election.

However, the market seems to pricing in these risks, with shares in Centrica currently trading on a P/E ratio of just 12 (versus 13.7 for the FTSE 100). Furthermore, shares in the company currently yield a highly impressive 5.5%, with dividends per share forecast to increase by 3.2% next year. Overall, Centrica seems to offer good value and considerable income potential.

Vodafone

Vodafone’s (LSE: VOD) current yield of 5.5% has come under a degree of scrutiny in recent months. That’s because it currently pays out more money as a dividend than it makes as a profit. As a result, the current level of dividend is unsustainable in the long run.

Despite this, Vodafone could prove to be an attractive income play. That’s because it appears to have a sound long term strategy that could deliver strong growth in profitability moving forward. Indeed, Vodafone’s purchase of high-quality, undervalued assets in Europe may take time to come good, but should ensure that the company is able to sustain an impressive yield in future years. As a result, it remains an attractive income play at current price levels.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of Centrica and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »